Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Rocket Pharmaceuticals, Inc.

Strategic Insights

— 1 min read

In a significant development, a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (NASDAQ: RKT) on behalf of investors who purchased or acquired the company's securities between September 17, 2024, and May 26, 2025, inclusive. The lawsuit alleges that the company made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. The complaint specifically alleges that Rocket knew about serious adverse events, including deaths of participants enrolled in the study, and failed to disclose this critical information to shareholders.

Key Takeaways:

  • The lawsuit alleges that Rocket Pharmaceuticals, Inc. made false and/or misleading statements about its business, operations, and prospects.
  • The company allegedly failed to disclose material adverse facts about its clinical trials, including serious adverse events and deaths of participants.
  • The lawsuit alleges that Rocket's positive statements about its business were materially misleading and/or lacked a reasonable basis.
  • The company has been placed on notice by the FDA, which has suspended the Phase 2 pivotal trial of its Danon disease treatment, RP-A501.
  • The lawsuit is open to all investors who purchased or acquired Rocket securities during the Class Period (September 17, 2024, to May 26, 2025).
  • The lead plaintiff motion deadline is August 11, 2025.

Statistics:

  • The class action lawsuit seeks to recover losses suffered by investors who purchased or acquired Rocket securities during the Class Period.
  • Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025.
  • The lawsuit alleges that Rocket knew about serious adverse events, including deaths of participants enrolled in the study.

Sources:

  • Globe Newswire: "Law Firm Announces Class Action Important Deadline in Shareholder Action Against Rocket Pharmaceuticals, Inc. - RKT" (August 1, 2025)
  • Glancy Prongay & Murray LLP: Press Release (August 1, 2025)

Read more